Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans

1 Mar 2019

Abstract excerpt

efficacy models that provide valuable and complementary information for dose selection and translation from the laboratory to human. It is crucial that studies be designed, conducted, and interpreted appropriately. For antibacterial PK/PD, extensive published data and expertise are available. These have been leveraged to develop recommendations, identify common pitfalls, and describe the applications, strengths,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Bacterial Identification and Susceptibility Testing
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30833428
DOI: 10.1128/aac.02307-18

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to HumansPMID 30833428Read ↗

[PK/PD of antimicrobials].Semantic proximity Read ↗

Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage DosingSemantic proximity Read ↗

Simultaneous in vitro simulation of multiple antimicrobial agents with different elimination half-lives in a pre-clinical infection modelSemantic proximity Read ↗

Revitalizing antibiotic discovery and development through in vitro modelling of in-patient conditionsSemantic proximity Read ↗

Establishing a framework for human dose prediction in anti-tuberculosis drug developmentSemantic proximity Read ↗

Lesion penetration predicts tuberculosis regimen success: a validated translational tool for de-risking late-stage drug developmentSemantic proximity Read ↗

Pharmacokinetic and Pharmacodynamic Obstacles for Phage Therapy From the Perspective of Clinical PracticeSemantic proximity Read ↗

Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergenceSemantic proximity Read ↗

Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in ChildrenSemantic proximity Read ↗

Combination of <i>in vivo</i> phage therapy data with <i>in silico</i> model highlights key parameters for treatment efficacySemantic proximity Read ↗

Introducing the new face of CLSI M100 in 2023: An explanatory reviewSemantic proximity Read ↗

Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.